Schizophrenia, First-Episode Psychosis (FEP), At-Risk Mental State (ARMS), Healthy Control
Conditions
Interventions
A series of assessments conducted in healthy individuals
A series of assessments conducted in patients
Sponsors
University of Toyama
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who are currently receiving outpatient or inpatient treatment at the Department of Neuropsychiatry, University of Toyama Hospital, and who meet the diagnostic criteria for schizophrenia (F20) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) or the International Classification of Diseases, 10th Revision (ICD-10) will be included. Individuals identified as being at clinical high risk for psychosis (At-Risk Mental State; ARMS) based on the Comprehensive Assessment of At-Risk Mental States (CAARMS; Yung et al., 2005), a structured interview for assessing risk of psychosis, will also be included. Patients who meet the ICD-10 criteria for Persistent Delusional Disorder (F22), Acute and Transient Psychotic Disorder (F23), or Mood Disorders with Psychotic Features (F32.3, F31.2, F31.5) will be included as first-episode psychosis cases. In addition, healthy control participants without any past or family history of psychiatric disorders will be recruited through the University of Toyama website and related media. Eligible participants will be between 12 and 50 years of age. For adult participants, written informed consent will be obtained from the individual. For minors, in principle, consent will be obtained from both the participant and their parent or guardian.
Exclusion criteria
Exclusion criteria: Participants will be excluded if any of the following apply: [Healthy Control Group] A history of neurological disease or severe head injury. A history of alcohol or substance abuse within the past five years. Presence of any Axis I psychiatric disorder as determined by the Structured Clinical Interview for DSM Disorders, Non-Patient Edition (SCID-NP), or a first-degree relative (parent, sibling, or child) with an Axis I psychiatric disorder based on participant report. [Patient Group] Psychiatric symptoms are clearly attributable to delirium, or to alcohol or substance abuse. The researcher determines that the psychiatric condition is unstable and that participation in the study, including examinations or explanations, may cause symptom exacerbation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Autoantibodies against neurotransmission-related molecules in blood Examinations will be conducted five times in principle (at baseline, 6 months, 1 year, 2 years, and 5 years). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Biological Examinations Brain MRI Resting-state EEG Event-related potentials (P300, mismatch negativity) auditory steady state response (ASSR) Erythrocyte membrane fatty acid composition Advanced glycation end products (AGEs) 2. Clinical and Cognitive Assessments Comprehensive Assessment of At-Risk Mental States (CAARMS) Positive and Negative Syndrome Scale (PANSS) Brief Assessment of Cognition in Schizophrenia (BACS) Schizophrenia Cognition Rating Scale (SCoRS) Global Assessment of Functioning (GAF) Social and Occupational Functioning Assessment Scale (SOFAS) Quality of Life Scale (QLS) 3. Clinical Information Educational and occupational history Date of first visit and duration of outpatient treatment Comorbid psychiatric disorders Treatment history (medications and duration of administration) | — |
Countries
Japan
Contacts
Public ContactYuko Higuchi
Graduate School of Medicine and Pharmaceutical Sciences,University of Toyama Department of Neuropsychiatry
Outcome results
None listed